“Spesolimab Decreases Generalized Pustular Psoriasis (GPP) Body Surface Area (BSA) over Time in Patients Switching from Conventional Systemic Treatments: Results from the EFFISAYIL® 2 Trial”. SKIN The Journal of Cutaneous Medicine 8, no. 6 (November 18, 2024): s488. Accessed May 19, 2026. https://skin.dermsquared.com/skin/article/view/3132.